Restoring Sight: The Journey of AIPL1 from Discovery to Therapy.

Alima Galieva, Alexander Karabelsky, Alexander D Egorov

Abstract readReview

In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alima GalievaGene Therapy Department, Center for Translational Medicine, Sirius University of Science and Technology, 354340 Sirius, Russia.ORCID 0000-0001-8190-0710

Alexander KarabelskyGene Therapy Department, Center for Translational Medicine, Sirius University of Science and Technology, 354340 Sirius, Russia.ORCID 0000-0002-6391-5182

Alexander D EgorovGene Therapy Department, Center for Translational Medicine, Sirius University of Science and Technology, 354340 Sirius, Russia.ORCID 0000-0002-5953-8097

Funding

Ministry of Science and Higher Education of the Russian Federation Agreement No 075-10-2025-017 from the 27.02.2025 project (GTH-RND-2011).

6 · The paper itself

Abstract

Leber congenital amaurosis (LCA) is a severe inherited retinal disorder manifesting at birth or in early infancy, with a subset of cases linked to mutations in the aryl hydrocarbon receptor-interacting protein-like 1 (

Indexed as

Adaptor Proteins, Signal TransducingEye ProteinsLeber Congenital AmaurosisAnimalsGenetic TherapyHumansMutationRetinal DegenerationAdaptor Proteins, Signal TransducingAIPL1 protein, humanEye Proteinsadeno-associated virusAIPL1aryl hydrocarbon receptor interacting proteinaryl hydrocarbon receptor interacting protein-like 1gene therapyinherited retinal diseasesLeber congenital amaurosisLeber congenital amaurosis type 4photoreceptorsvision

Identifiers

PMID41465493

DOI10.3390/ijms262412066

PMCPMC12733016

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.